**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giorgia CANALI, Pfizer, Paris, France

**Main Body of the Abstract**
Introduction: The diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is complex, including numerous examinations and implicating different medical specialists. DIAM-ATTR survey aimed to obtain a snapshot of the current ATTR-CM diagnostic pathway via an electronic survey. Almost 70% of the 20.067 French healthcare professionals (HCPs) potentially implicated in ATTR-CM diagnosis, both public and private practice throughout France, were contacted. The “Réseau Amylose” and “Filière Cardiogen” were implicated. Levels of knowledge on ATTR-CM, use of recommended diagnostic algorithm, diagnostic pathway, as well as the difficulties encountered during diagnosis, overall and according to each specialty, were collected.
Results:1264 physicians from 7 different specialties returned the survey. The levels of knowledge with respect to the signs and symptoms suggesting ATTR-CM differed between HCPs according to specialty, see figure 1. Regarding the diagnostic pathway, among the 719 HCPs diagnosing ATTR-CM, most adhere to the current diagnostic algorithm with almost all respondents performing bone scintigraphy and monoclonal gammopathy. However, some diagnostic examinations such as genetic testing were not systematically performed (59% to 93% depending on specialty). The healthcare pathway, as well as difficulties encountered for ATTR-CM diagnosis varied among specialities. The predominant difficulty pertained to confirming the type of amyloidosis by biopsy.
Conclusion: The French DIAM-ATTR survey shows that the recommended diagnostic algorithm is mostly followed although further HCPs education on clinical signs associated with ATTR-CM is needed. The survey identified several difficulties in the diagnostic pathway of the disease that should be overcome to improve ATTR-CM patients management.
Funding: Sponsored by Carely, founding by Pfizer.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giorgia CANALI, Pfizer, Paris, France

**Main Body of the Abstract**
**Introduction:** The diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is complex, including numerous examinations and implicating different medical specialists. DIAM-ATTR survey aimed to obtain a snapshot of the current ATTR-CM diagnostic pathway _via_ an electronic survey. Almost 70% of the 20.067 French healthcare professionals (HCPs) potentially implicated in ATTR-CM diagnosis, both public and private practice throughout France, were contacted. The “Réseau Amylose” and “Filière Cardiogen” were implicated. Levels of knowledge on ATTR-CM, use of recommended diagnostic algorithm, diagnostic pathway, as well as the difficulties encountered during diagnosis, overall and according to each specialty, were collected.
**Results**:1264 physicians from 7 different specialties returned the survey. The levels of knowledge with respect to the signs and symptoms suggesting ATTR-CM differed between HCPs according to specialty, see **figure 1**. Regarding the diagnostic pathway, among the 719 HCPs diagnosing ATTR-CM, most adhere to the current diagnostic algorithm with almost all respondents performing bone scintigraphy and monoclonal gammopathy. However, some diagnostic examinations such as genetic testing were not systematically performed (59% to 93% depending on specialty). The healthcare pathway, as well as difficulties encountered for ATTR-CM diagnosis varied among specialities. The predominant difficulty pertained to confirming the type of amyloidosis by biopsy.
**Conclusion**: The French DIAM-ATTR survey shows that the recommended diagnostic algorithm is mostly followed although further HCPs education on clinical signs associated with ATTR-CM is needed. The survey identified several difficulties in the diagnostic pathway of the disease that should be overcome to improve ATTR-CM patients management.
**Funding:** Sponsored by Carely, founding by Pfizer.



Evaluating the current physicians’ knowledge and patients’ pathways for diagnosing transthyretin cardiac amyloidosis (ATTR-CM) in France: An extensive survey of diverse medical specialists. PB55 (#85)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.